(JHX) James Hardie Industries - Overview
Stock: Fiber Cement, Siding, Trim, Gypsum Boards, Cement Boards
| Risk 5d forecast | |
|---|---|
| Volatility | 42.9% |
| Relative Tail Risk | -14.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.15 |
| Alpha | -37.82 |
| Character TTM | |
|---|---|
| Beta | 1.131 |
| Beta Downside | 1.006 |
| Drawdowns 3y | |
|---|---|
| Max DD | 60.26% |
| CAGR/Max DD | 0.11 |
EPS (Earnings per Share)
Revenue
Description: JHX James Hardie Industries January 03, 2026
James Hardie Industries plc (NYSE:JHX) manufactures and sells fiber cement, fiber gypsum, and cement-bonded boards across the United States, Australia, Europe, and New Zealand, operating under three geographic segments: North America Fiber Cement, Asia-Pacific Fiber Cement, and Europe Building Products.
The company’s product portfolio, marketed under the Hardie™ brand (e.g., Hardie Plank, Hardie Panel, Hardie Trim) and the fermacell and AESTUVER brands, serves both exterior applications-siding, cladding, soffit, trim-and interior uses such as walls, floors, ceilings, and fire-protection systems.
Key recent metrics: FY 2023 revenue reached approximately $2.1 billion, with an adjusted EBITDA margin of roughly 15 %; net debt/EBITDA stood at about 1.2×, indicating moderate leverage. The company reaffirmed FY 2024 revenue guidance of $2.2-$2.3 billion, driven by strong demand in the U.S. residential market.
Economic and sector drivers: (1) U.S. single-family housing starts, which have risen 8 % YoY, directly boost Hardie’s North American segment; (2) increasingly stringent building-code requirements for fire-resistant and moisture-durable materials favor fiber cement over traditional wood siding; (3) supply-chain constraints on timber and steel have shifted remodel and new-construction projects toward fiber-based alternatives.
For a deeper dive into Hardie’s valuation metrics and scenario analysis, see the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 119.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -6.01 > 1.0 |
| NWC/Revenue: 13.74% < 20% (prev 20.60%; Δ -6.86% < -1%) |
| CFO/TA 0.04 > 3% & CFO 600.1m > Net Income 119.1m |
| Net Debt (4.60b) to EBITDA (797.3m): 5.77 < 3 |
| Current Ratio: 1.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (583.1m) vs 12m ago 35.32% < -2% |
| Gross Margin: 35.86% > 18% (prev 0.39%; Δ 3546 % > 0.5%) |
| Asset Turnover: 47.06% > 50% (prev 79.68%; Δ -32.62% > 0%) |
| Interest Coverage Ratio: 2.23 > 6 (EBITDA TTM 797.3m / Interest Expense TTM 182.4m) |
Altman Z'' 1.30
| A: 0.04 (Total Current Assets 1.72b - Total Current Liabilities 1.11b) / Total Assets 13.80b |
| B: 0.13 (Retained Earnings 1.80b / Total Assets 13.80b) |
| C: 0.04 (EBIT TTM 407.4m / Avg Total Assets 9.36b) |
| D: 0.28 (Book Value of Equity 2.09b / Total Liabilities 7.41b) |
| Altman-Z'' Score: 1.30 = BB |
Beneish M -1.95
| DSRI: 1.04 (Receivables 316.8m/270.6m, Revenue 4.40b/3.91b) |
| GMI: 1.10 (GM 35.86% / 39.45%) |
| AQI: 2.51 (AQ_t 0.63 / AQ_t-1 0.25) |
| SGI: 1.13 (Revenue 4.40b / 3.91b) |
| TATA: -0.03 (NI 119.1m - CFO 600.1m) / TA 13.80b) |
| Beneish M-Score: -1.95 (Cap -4..+1) = B |
What is the price of JHX shares?
Over the past week, the price has changed by -3.35%, over one month by +8.23%, over three months by +40.94% and over the past year by -21.05%.
Is JHX a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the JHX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29.9 | 19.1% |
| Analysts Target Price | 29.9 | 19.1% |
JHX Fundamental Data Overview February 18, 2026
P/E Forward = 20.7039
P/S = 3.4084
P/B = 2.3463
P/EG = 1.1439
Revenue TTM = 4.40b USD
EBIT TTM = 407.4m USD
EBITDA TTM = 797.3m USD
Long Term Debt = 4.57b USD (from longTermDebt, last quarter)
Short Term Debt = 80.8m USD (from shortTermDebt, last quarter)
Debt = 4.97b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.60b USD (from netDebt column, last quarter)
Enterprise Value = 19.64b USD (15.01b + Debt 4.97b - CCE 344.2m)
Interest Coverage Ratio = 2.23 (Ebit TTM 407.4m / Interest Expense TTM 182.4m)
EV/FCF = 95.39x (Enterprise Value 19.64b / FCF TTM 205.9m)
FCF Yield = 1.05% (FCF TTM 205.9m / Enterprise Value 19.64b)
FCF Margin = 4.68% (FCF TTM 205.9m / Revenue TTM 4.40b)
Net Margin = 2.70% (Net Income TTM 119.1m / Revenue TTM 4.40b)
Gross Margin = 35.86% ((Revenue TTM 4.40b - Cost of Revenue TTM 2.82b) / Revenue TTM)
Gross Margin QoQ = 36.15% (prev 32.59%)
Tobins Q-Ratio = 1.42 (Enterprise Value 19.64b / Total Assets 13.80b)
Interest Expense / Debt = 1.32% (Interest Expense 65.6m / Debt 4.97b)
Taxrate = 37.88% (41.9m / 110.6m)
NOPAT = 253.1m (EBIT 407.4m * (1 - 37.88%))
Current Ratio = 1.54 (Total Current Assets 1.72b / Total Current Liabilities 1.11b)
Debt / Equity = 0.78 (Debt 4.97b / totalStockholderEquity, last quarter 6.40b)
Debt / EBITDA = 5.77 (Net Debt 4.60b / EBITDA 797.3m)
Debt / FCF = 22.34 (Net Debt 4.60b / FCF TTM 205.9m)
Total Stockholder Equity = 4.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.27% (Net Income 119.1m / Total Assets 13.80b)
RoE = 2.78% (Net Income TTM 119.1m / Total Stockholder Equity 4.28b)
RoCE = 4.60% (EBIT 407.4m / Capital Employed (Equity 4.28b + L.T.Debt 4.57b))
RoIC = 3.33% (NOPAT 253.1m / Invested Capital 7.60b)
WACC = 7.77% (E(15.01b)/V(19.98b) * Re(10.08%) + D(4.97b)/V(19.98b) * Rd(1.32%) * (1-Tc(0.38)))
Discount Rate = 10.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 15.34%
[DCF Debug] Terminal Value 78.44% ; FCFF base≈270.7m ; Y1≈261.7m ; Y5≈258.8m
Fair Price DCF = 0.33 (EV 4.79b - Net Debt 4.60b = Equity 190.1m / Shares 579.9m; r=7.77% [WACC]; 5y FCF grow -4.56% → 2.90% )
EPS Correlation: -61.85 | EPS CAGR: -12.61% | SUE: 0.14 | # QB: 0
Revenue Correlation: 49.09 | Revenue CAGR: 6.82% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.29 | Chg30d=+0.003 | Revisions Net=+0 | Analysts=3
EPS next Year (2027-03-31): EPS=1.39 | Chg30d=+0.202 | Revisions Net=+1 | Growth EPS=+22.0% | Growth Revenue=+15.0%